News

Tenax Therapeutics has been granted another U.S. patent for levosimendan, this one covering all three routes of administration and its active metabolites, for the treatment of people with PH-HFpEF, or pulmonary hypertension and heart failure with preserved ejection fraction. Issued by the U.S. Patent and Trademark Office, the…

Low levels of PM20D1, a molecule involved in metabolizing lipids, were identified as a risk factor for mortality in people with pulmonary arterial hypertension (PAH), a study reports. As a result, PM20D1, or peptidase M20 domain containing 1, may be a biomarker of disease prognosis, according to scientists. Lipid…

Two genes were identified as potential drivers of pulmonary arterial hypertension (PAH) in people with HIV-1 infection in a bioinformatics study, offering new perspectives to uncover the underlying molecular mechanisms that link HIV infection and PAH. The genes ISG15 and IFI27 are established hub genes involved in the type…

More than 80 organizations globally, including the U.S.-based Pulmonary Hypertension Association (PHA), will unite on May 5 for World Pulmonary Hypertension Day, celebrated annually to heighten awareness of pulmonary hypertension (PH), which affects an estimated 75 million people worldwide. This year’s global initiative is led by PHA Europe,…

MACC1, a gene that’s been linked to overgrowth of cancer cells, is more active in the lungs of people with pulmonary arterial hypertension (PAH) than in healthy individuals, a study out of China found, suggesting it could be used as a diagnostic biomarker for the disease. Researchers also observed…

Low levels of circular RNA Alstrom syndrome protein 1, or circALMS1, may be associated with poor outcomes with pulmonary hypertension (PH), a study suggests. This may be because low circALMS1 levels promote higher numbers and the migration of pulmonary microvascular endothelial cells (PMECs), and reduce the cells’ death. PMECs…

As of April 15, Opsynvi (macitentan and tadalafil) — the first single-tablet treatment combination approved by the U.S. Food and Drug Administration (FDA) for pulmonary arterial hypertension (PAH) — is available to eligible patients in the U.S. through a specialty pharmacy network. With its launch, PAH patients who…

Despite more women being affected by pulmonary hypertension (PH), men with the cardiovascular disease had worse right ventricular function and lower odds of transplant-free survival relative to their female counterparts, a study found. In a large group of patients with various types of PH, sex differences in function of…

Most people with pulmonary arterial hypertension (PAH) due to connective tissue disease (CTD) who are using Opsumit (macitenan) do so as part of a combination therapy, according to real-world evidence from two U.S. drug registry studies. Its safety and effectiveness, in terms of clinical outcomes, for these patients…

The American Kidney Fund (AKF) has awarded an early-career fellowship that will support new research aiming to understand how pulmonary hypertension (PH) develops in people with chronic kidney disease. The project will be led by Marcelle Tuttle, MD, a first-year fellow at the Tufts Medical Center division of…

Note: This story was updated April 11, 2024, to remove reference to Acceleron Pharma, now a wholly owned subsidiary of Merck.  Winrevair (sotatercept-csrk), the under-the-skin injectable treatment recently approved in the U.S. for adults with pulmonary arterial hypertension (PAH), is expected to be available…

Having pulmonary hypertension (PH) worsens the likelihood of potentially life-threatening cardiac and respiratory complications in people with human immunodeficiency virus (HIV) infection, a U.S. database study reported. Its findings “can inform clinical practice and help healthcare providers make more informed decisions regarding the screening, diagnosis, and management of PH…